Satyender Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Satyender Kumar has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Vinod Jairaj
Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad
3 shared publicationsPrakash Niguram
Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad
2 shared publicationsPriyank Purohit
Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, 1-Knowledge Park, Phase II, Greater Noida - 201 306, Uttar Pradesh, India
2 shared publicationsSeema Dagar
Department of Pharmaceutical Administration and Management, Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra - 136 119, Haryana, India
2 shared publications- Ajay Kumar
Sharda University
1 shared publication Aloisio Mateus Fiuza Sanha
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 6 (4) , 21-30
Design, optimization, and characterization of curcumin-loaded proniosomal vesicular systems as a novel phytopharmaceutical delivery strategy for psoriasis management
Herbal therapeutics such as curcumin have potent anti-inflammatory and antioxidant potential but face challenges of low solubility, poor bioavailability, and instability. Proniosomes, surfactant-coated dry vesicular carriers, offer enhanced stability, scalability, and bioavailability, making them suitable for delivering insoluble herbal actives through topical applications. This study was designed to develop and optimize curcumin-loaded Proniosomes using Box-Behnken Design (BBD) to improve physicochemical features for psoriasis management. Proniosomes were prepared by antisolvent precipitation using Span 80, soya lecithin, and cholesterol. A three-factor, three-level BBD was applied to evaluate the effect of Span (X₁), lecithin (X₂), and cholesterol (X₃) on critical quality attributes: particle size (Y₁), zeta potential (Y₂), and PDI (Y₃). Seventeen runs were performed and statistically analyzed using ANOVA, Pearson’s correlation, and lack-of-fit testing. Entrapment efficiency and in vitro drug release were further measured. Formulations showed particle sizes of 143–366 nm, zeta potential of 14–32 mV, and PDI of 0.045–0.53. The optimized batch exhibited ~206 nm particle size, ~24 mV zeta potential, and 0.22 PDI. Entrapment efficiency reached ~84%, while drug release was sustained over 24 h, with ~96.64% cumulative release at 48 h compared to ~25.5% for pure curcumin. Enhanced release was attributed to the amphiphilic surfactants forming stable bilayered vesicles, and cholesterol providing structural integrity for controlled release. In conclusion, optimized curcumin Proniosomes established high stability, scalability, entrapment, and sustained release, providing a promising topical delivery platform for effective psoriasis management.
- 30 June 2026
- Published by Visagaa Publishing House in Natural Resources for Human Health
- Vol. 6 (4) , 21-30
Open AccessDesign, optimization, and characterization of curcumin-loaded proniosomal vesicular systems as a novel phytopharmaceutical delivery strategy for psoriasis management
Herbal therapeutics such as curcumin have potent anti-inflammatory and antioxidant potential but face challenges of low solubility, poor bioavailability, and instability. Proniosomes, surfactant-coated dry vesicular carriers, offer enhanced stability, scalability, and bioavailability, making them suitable for delivering insoluble herbal actives through topical applications. This study was designed to develop and optimize curcumin-loaded Proniosomes using Box-Behnken Design (BBD) to improve physicochemical features for psoriasis management. Proniosomes were prepared by antisolvent precipitation using Span 80, soya lecithin, and cholesterol. A three-factor, three-level BBD was applied to evaluate the effect of Span (X₁), lecithin (X₂), and cholesterol (X₃) on critical quality attributes: particle size (Y₁), zeta potential (Y₂), and PDI (Y₃). Seventeen runs were performed and statistically analyzed using ANOVA, Pearson’s correlation, and lack-of-fit testing. Entrapment efficiency and in vitro drug release were further measured. Formulations showed particle sizes of 143–366 nm, zeta potential of 14–32 mV, and PDI of 0.045–0.53. The optimized batch exhibited ~206 nm particle size, ~24 mV zeta potential, and 0.22 PDI. Entrapment efficiency reached ~84%, while drug release was sustained over 24 h, with ~96.64% cumulative release at 48 h compared to ~25.5% for pure curcumin. Enhanced release was attributed to the amphiphilic surfactants forming stable bilayered vesicles, and cholesterol providing structural integrity for controlled release. In conclusion, optimized curcumin Proniosomes established high stability, scalability, entrapment, and sustained release, providing a promising topical delivery platform for effective psoriasis management.
- 11 June 2026
- Published by Bentham Science Publishers Ltd. in Current Neurovascular Research
- Vol. 23, 1-11
The Relationship between Traumatic Brain Injury and Systemic Health: Dissecting the Somatic and Neurological Effects
Introduction: Traumatic brain injury (TBI) is a neurological disorder caused by external biomechanical forces such as sports impacts and vehicular accidents. It is a leading cause of morbidity and long-term disability across all age groups. Beyond acute damage, TBI contributes to chronic neurodegenerative processes and persistent neurological sequelae. Growing clinical and experimental evidence suggests that TBI is also associated with systemic alterations affecting the cardiovascular, respiratory, renal, gastrointestinal, and immune systems. Methods: This narrative integrative review synthesized recent experimental and clinical studies investigating neurological and systemic complications following TBI. Sources were evaluated for evidence related to neurodegenerative cascades, organ dysfunction, and immune-mediated mechanisms. Findings from animal models and human studies were interpreted contextually to highlight mechanistic insights and clinical relevance. Results: The reviewed literature indicates that TBI is associated with both acute and chronic neurological impairment, while also affecting peripheral organ systems. Reported alterations include cardiovascular instability, pulmonary dysfunction, renal hypoperfusion, gastrointestinal barrier disruption, hepatic cytotoxicity, and immune dysregulation. Several studies suggest that peripheral immune activation may contribute to secondary neuroinflammatory processes and unfavorable neurological outcomes. Discussion: The bidirectional interactions between the injured brain and peripheral organs represent a critical but incompletely understood aspect of TBI pathology. Systemic complications may amplify neuroinflammatory cascades and are increasingly recognized as contributors to progressive neurological decline. Integrating brain-systemic perspectives is essential to better understand the multisystem consequences of TBI. Conclusion: TBI is increasingly recognized as a multisystem condition that extends beyond the central nervous system. Improved understanding of brain–systemic interactions may inform the development of therapeutic strategies targeting both neurological injury and associated systemic complications, with the potential to reduce morbidity and mortality following head injury.
- 11 June 2026
- Published by Bentham Science Publishers Ltd. in Current Neurovascular Research
- Vol. 23, 1-11
The Relationship between Traumatic Brain Injury and Systemic Health: Dissecting the Somatic and Neurological Effects
Introduction: Traumatic brain injury (TBI) is a neurological disorder caused by external biomechanical forces such as sports impacts and vehicular accidents. It is a leading cause of morbidity and long-term disability across all age groups. Beyond acute damage, TBI contributes to chronic neurodegenerative processes and persistent neurological sequelae. Growing clinical and experimental evidence suggests that TBI is also associated with systemic alterations affecting the cardiovascular, respiratory, renal, gastrointestinal, and immune systems. Methods: This narrative integrative review synthesized recent experimental and clinical studies investigating neurological and systemic complications following TBI. Sources were evaluated for evidence related to neurodegenerative cascades, organ dysfunction, and immune-mediated mechanisms. Findings from animal models and human studies were interpreted contextually to highlight mechanistic insights and clinical relevance. Results: The reviewed literature indicates that TBI is associated with both acute and chronic neurological impairment, while also affecting peripheral organ systems. Reported alterations include cardiovascular instability, pulmonary dysfunction, renal hypoperfusion, gastrointestinal barrier disruption, hepatic cytotoxicity, and immune dysregulation. Several studies suggest that peripheral immune activation may contribute to secondary neuroinflammatory processes and unfavorable neurological outcomes. Discussion: The bidirectional interactions between the injured brain and peripheral organs represent a critical but incompletely understood aspect of TBI pathology. Systemic complications may amplify neuroinflammatory cascades and are increasingly recognized as contributors to progressive neurological decline. Integrating brain-systemic perspectives is essential to better understand the multisystem consequences of TBI. Conclusion: TBI is increasingly recognized as a multisystem condition that extends beyond the central nervous system. Improved understanding of brain–systemic interactions may inform the development of therapeutic strategies targeting both neurological injury and associated systemic complications, with the potential to reduce morbidity and mortality following head injury.
- Open Access
- 12 September 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (9) , 1187
Development of pH-Sensitive Multiparticulates for Orally Disintegrating Tablets of Proton Pump Inhibitors: Physicochemical Characterization and Drug Release Studies
Background/Objectives: Enteric coating protects active pharmaceutical ingredients from gastric degradation, but conventional tablets may present swallowing difficulties in geriatric and pediatric patients. Hence, this study intended to develop pH-responsive multiparticulates, formulated into orally disintegrating tablets (ODTs), for targeted intestinal drug delivery in individuals with dysphagia. Methods: Multiparticulates were developed via sequential seal coating, drug layering, sub-coating, and enteric coating on inert cores using a fluidized bed coater (Pam Glatt, India; bottom spray). Selected enteric-coated batches were directly compressed into ODTs using microcrystalline cellulose (Avicel PH102) and mannitol (Pearlitol SD 160) as fillers, with Explotab®, Ac-Di-Sol®, or crospovidone M® as superdisintegrants. Results: Multiparticulates exhibited mean diameters of 197.671–529.511 μm and span values of 0.603–0.838. Span value < 1, indicating a narrow size distribution. Electron microscopy confirmed the spherical morphology of Batches 7a and b. Enteric-coated batches (5b, 6, 7a, 7b) released ≤10% of the drug in 0.1 N HCl at 2 h. Optimized formulation ODT 7b released 7.904% of the drug under gastric conditions and 79.749% in phosphate buffer (pH 6.8) within 2.5 h, following first-order drug release kinetics. ODT 7b demonstrated hardness (2.538 ± 0.144 kg/cm2), wetting time (11.17 ± 1.051 s), friability (0.712%), and drug content (99.81 ± 1.01%) within acceptable limits. Conclusions: The pH-dependent multiparticulates provided sustained intestinal drug release and, when incorporated into ODTs, yielded a dosage form with a rapid wetting time and acceptable mechanical properties. This dosage form can offer a promising approach for improving compliance and therapeutic efficacy in patients with swallowing difficulties (dysphagia).
- 12 September 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (9) , 1187
Open AccessDevelopment of pH-Sensitive Multiparticulates for Orally Disintegrating Tablets of Proton Pump Inhibitors: Physicochemical Characterization and Drug Release Studies
Background/Objectives: Enteric coating protects active pharmaceutical ingredients from gastric degradation, but conventional tablets may present swallowing difficulties in geriatric and pediatric patients. Hence, this study intended to develop pH-responsive multiparticulates, formulated into orally disintegrating tablets (ODTs), for targeted intestinal drug delivery in individuals with dysphagia. Methods: Multiparticulates were developed via sequential seal coating, drug layering, sub-coating, and enteric coating on inert cores using a fluidized bed coater (Pam Glatt, India; bottom spray). Selected enteric-coated batches were directly compressed into ODTs using microcrystalline cellulose (Avicel PH102) and mannitol (Pearlitol SD 160) as fillers, with Explotab®, Ac-Di-Sol®, or crospovidone M® as superdisintegrants. Results: Multiparticulates exhibited mean diameters of 197.671–529.511 μm and span values of 0.603–0.838. Span value < 1, indicating a narrow size distribution. Electron microscopy confirmed the spherical morphology of Batches 7a and b. Enteric-coated batches (5b, 6, 7a, 7b) released ≤10% of the drug in 0.1 N HCl at 2 h. Optimized formulation ODT 7b released 7.904% of the drug under gastric conditions and 79.749% in phosphate buffer (pH 6.8) within 2.5 h, following first-order drug release kinetics. ODT 7b demonstrated hardness (2.538 ± 0.144 kg/cm2), wetting time (11.17 ± 1.051 s), friability (0.712%), and drug content (99.81 ± 1.01%) within acceptable limits. Conclusions: The pH-dependent multiparticulates provided sustained intestinal drug release and, when incorporated into ODTs, yielded a dosage form with a rapid wetting time and acceptable mechanical properties. This dosage form can offer a promising approach for improving compliance and therapeutic efficacy in patients with swallowing difficulties (dysphagia).
- 1 June 2025
- Published by Bentham Science Publishers Ltd. in Applied Drug Research, Clinical Trials and Regulatory Affairs
- Vol. 11, 1-11
Impact of Contract Research Organizations on Pharmaceutical Industries: A Review
Contract Research Organizations are bodies that offer research and development services on a contract basis to the pharmaceutical, biotechnology, medical device, and other industries. These organizations offer a wide range of services to support the drug discovery, development, and commercialization process. Initially, CROs begin with clinical trial management facilities and assisting sponsors with clinical study design, whereas laboratory CROs provide drug discovery, manufacturing, and bioanalytical services, including site feasibility. Their services mainly cover pharmaceutical and biotechnology industry based work such as drug development, pharmaceutical product development, clinical and preclinical trials, analytical method developments, pharmacovigilance, medical writing, etc. India presents itself as a wonderful platform for CROs attributing to its huge population, varied disease conditions, accessible human resources, large number of hospitals and low treatment cost. In the clinical trial process, CROs are engaged by the sponsor to accomplish a number of duties, taking into account various administrative and technical responsibilities on behalf of the sponsor. The current manuscript highlights the globalization of clinical trials, the concept of CRO, roles and responsibilities, functions of CROs, regulatory infrastructure of CRO, criteria for selection of suitable CRO, Indian CRO market and impact of COVID-19 pandemic on it.
- 1 June 2025
- Published by Bentham Science Publishers Ltd. in Applied Drug Research, Clinical Trials and Regulatory Affairs
- Vol. 11, 1-11
Impact of Contract Research Organizations on Pharmaceutical Industries: A Review
Contract Research Organizations are bodies that offer research and development services on a contract basis to the pharmaceutical, biotechnology, medical device, and other industries. These organizations offer a wide range of services to support the drug discovery, development, and commercialization process. Initially, CROs begin with clinical trial management facilities and assisting sponsors with clinical study design, whereas laboratory CROs provide drug discovery, manufacturing, and bioanalytical services, including site feasibility. Their services mainly cover pharmaceutical and biotechnology industry based work such as drug development, pharmaceutical product development, clinical and preclinical trials, analytical method developments, pharmacovigilance, medical writing, etc. India presents itself as a wonderful platform for CROs attributing to its huge population, varied disease conditions, accessible human resources, large number of hospitals and low treatment cost. In the clinical trial process, CROs are engaged by the sponsor to accomplish a number of duties, taking into account various administrative and technical responsibilities on behalf of the sponsor. The current manuscript highlights the globalization of clinical trials, the concept of CRO, roles and responsibilities, functions of CROs, regulatory infrastructure of CRO, criteria for selection of suitable CRO, Indian CRO market and impact of COVID-19 pandemic on it.
- 29 May 2024
- Published by Walter de Gruyter GmbH in Journal of Complementary and Integrative Medicine
- Vol. 21 (3) , 360-369
Pharmacognostical characterization, GC-MS profiling, and elemental analysis of Curcuma caesia Roxb. rhizomes for public health
Objectives: The study provides a thorough examination of the rhizomes of Curcuma caesia Roxb., which is a medicinal substance sometimes referred to as black turmeric and has not been well studied. Methods: The study examines the pharmacognostical characteristics, GC-MS profiling, and elemental analysis of the substance to determine its potential for use in medicine. The presence of heavy metal contamination in herbal products is a significant issue, which necessitates the use of Atomic Absorption Spectrophotometry to quantitatively analyze eight elements. Results: The investigation validates the existence of crucial trace elements while guaranteeing that the levels of heavy metals are within the toxicity limits set by the World Health Organization. This indicates that the rhizome is safe for medicinal purposes. The selection of a solvent has a substantial impact on the efficiency of extraction. Acetone has the highest extraction yield, followed by ethanol and ethyl acetate. The GC-MS analysis uncovers a wide range of phytochemicals, such as alkaloids, flavonoids, phenols, tannins, steroids, and proteins. Additionally, particular solvents exclusively detect specific molecules. Epicurzerenone and zederone are chemicals that show promise for use in reducing inflammation and fighting cancer. Conclusions: On the basis of results it can be concluded that rhizome’s quality based on acceptable physicochemical characteristics and provides a strong basis for future pharmacological research. The research has potential for the development of novel organic drugs, utilizing the abundant phytochemical composition of C. caesia Roxb. rhizomes.
- 29 May 2024
- Published by Walter de Gruyter GmbH in Journal of Complementary and Integrative Medicine
- Vol. 21 (3) , 360-369
Pharmacognostical characterization, GC-MS profiling, and elemental analysis of Curcuma caesia Roxb. rhizomes for public health
Objectives: The study provides a thorough examination of the rhizomes of Curcuma caesia Roxb., which is a medicinal substance sometimes referred to as black turmeric and has not been well studied. Methods: The study examines the pharmacognostical characteristics, GC-MS profiling, and elemental analysis of the substance to determine its potential for use in medicine. The presence of heavy metal contamination in herbal products is a significant issue, which necessitates the use of Atomic Absorption Spectrophotometry to quantitatively analyze eight elements. Results: The investigation validates the existence of crucial trace elements while guaranteeing that the levels of heavy metals are within the toxicity limits set by the World Health Organization. This indicates that the rhizome is safe for medicinal purposes. The selection of a solvent has a substantial impact on the efficiency of extraction. Acetone has the highest extraction yield, followed by ethanol and ethyl acetate. The GC-MS analysis uncovers a wide range of phytochemicals, such as alkaloids, flavonoids, phenols, tannins, steroids, and proteins. Additionally, particular solvents exclusively detect specific molecules. Epicurzerenone and zederone are chemicals that show promise for use in reducing inflammation and fighting cancer. Conclusions: On the basis of results it can be concluded that rhizome’s quality based on acceptable physicochemical characteristics and provides a strong basis for future pharmacological research. The research has potential for the development of novel organic drugs, utilizing the abundant phytochemical composition of C. caesia Roxb. rhizomes.
- 7 May 2024
- Published by Walter de Gruyter GmbH in Journal of Complementary and Integrative Medicine
- Vol. 22 (2) , 213-227
Unveiling the phyto-restorative potential of ethereal distillates for atopic dermatitis: an advanced therapeutic approach
Atopic dermatitis is acknowledged as a vital inflammatory disorder associated with the integumentary system of the body and is characterized by the formation of thick reddish-grey scars and erythema formation on skin, prevalent amidst the populace. Numerous synthetic drugs are available for treatment like antihistamines, immunosuppressants, glucocorticoids etc., but contrarily, essential oil therapy is exclusively lime lighted to favour the purpose. The utilization of available engineered drugs, possess the marked adverse effects owing to prolonged duration of therapy and therefore, essential oils are explored well and proved to exhibit the anti-eczematic, anti-inflammatory and antipruritic properties. Ethereal distillates own the assorted and selective therapeutic properties attributable to presence of bioactive compounds liable to treat this torturous and integumentary disorder, likely lavender oil, patchouli oil, frankincense oil etc., have been found to exert their pharmacological actions by impeding the liberation and action of inflammatory mediators and immunological hyperactivities that are engaged in exacerbating this idiopathic illness. The current attempt provided the update with the aim to bring forth the naturally originated treatment that is pertinent to provide the invulnerable therapy by circumventing the noxious symptoms i.e. erythema formation and inflamed lesions.
- 7 May 2024
- Published by Walter de Gruyter GmbH in Journal of Complementary and Integrative Medicine
- Vol. 22 (2) , 213-227
Unveiling the phyto-restorative potential of ethereal distillates for atopic dermatitis: an advanced therapeutic approach
Atopic dermatitis is acknowledged as a vital inflammatory disorder associated with the integumentary system of the body and is characterized by the formation of thick reddish-grey scars and erythema formation on skin, prevalent amidst the populace. Numerous synthetic drugs are available for treatment like antihistamines, immunosuppressants, glucocorticoids etc., but contrarily, essential oil therapy is exclusively lime lighted to favour the purpose. The utilization of available engineered drugs, possess the marked adverse effects owing to prolonged duration of therapy and therefore, essential oils are explored well and proved to exhibit the anti-eczematic, anti-inflammatory and antipruritic properties. Ethereal distillates own the assorted and selective therapeutic properties attributable to presence of bioactive compounds liable to treat this torturous and integumentary disorder, likely lavender oil, patchouli oil, frankincense oil etc., have been found to exert their pharmacological actions by impeding the liberation and action of inflammatory mediators and immunological hyperactivities that are engaged in exacerbating this idiopathic illness. The current attempt provided the update with the aim to bring forth the naturally originated treatment that is pertinent to provide the invulnerable therapy by circumventing the noxious symptoms i.e. erythema formation and inflamed lesions.
- 15 April 2024
- Published by Taylor & Francis in Natural Product Research
- Vol. 39 (16) , 4563-4567
Exploring the potential of semi-synthetic Swertiamarin analogues for GLUT facilitation and insulin secretion in NIT-1 cell lines: a molecular docking and in-vitro study
Synthesis, characterisation, and anti-diabetic potential of swertiamarin analogues against DPP-4 enzymatic inhibition was done prior to this study. However, swertiamarin and its analogues inhibited DPP-4 enzyme significantly. Semisynthetic swertiamarin analogues have been studied for antidiabetic potential and mechanism of action utilising molecular docking and in-vitro techniques. The mechanism of action for swertiamarin analogues was determined by in-silico molecular docking studies using glucose-transporters, GLUT-1 (PDB ID: 4PYP), GLUT-3 (PDB ID: 7SPS), and GLUT-4 (PDB ID: 7WSM) along with in-vitro glucose uptake and glucose-induced insulin secretion assays. These studies found that synthesised swertiamarin analogues SNIPERSV3, SNIPERSV4, and SNIPERSV7 shown better docking score against different GLUTs and better anti-diabetic effects on glucose uptake and insulin secretion in NIT-1 cell line than standard glibenclamide and swertiamarin. Thus, swertiamarin analogues might be studied for diabetes therapy in the future.
- 15 April 2024
- Published by Taylor & Francis in Natural Product Research
- Vol. 39 (16) , 4563-4567
Exploring the potential of semi-synthetic Swertiamarin analogues for GLUT facilitation and insulin secretion in NIT-1 cell lines: a molecular docking and in-vitro study
Synthesis, characterisation, and anti-diabetic potential of swertiamarin analogues against DPP-4 enzymatic inhibition was done prior to this study. However, swertiamarin and its analogues inhibited DPP-4 enzyme significantly. Semisynthetic swertiamarin analogues have been studied for antidiabetic potential and mechanism of action utilising molecular docking and in-vitro techniques. The mechanism of action for swertiamarin analogues was determined by in-silico molecular docking studies using glucose-transporters, GLUT-1 (PDB ID: 4PYP), GLUT-3 (PDB ID: 7SPS), and GLUT-4 (PDB ID: 7WSM) along with in-vitro glucose uptake and glucose-induced insulin secretion assays. These studies found that synthesised swertiamarin analogues SNIPERSV3, SNIPERSV4, and SNIPERSV7 shown better docking score against different GLUTs and better anti-diabetic effects on glucose uptake and insulin secretion in NIT-1 cell line than standard glibenclamide and swertiamarin. Thus, swertiamarin analogues might be studied for diabetes therapy in the future.
- 1 October 2020
- Published by Taylor & Francis in Natural Product Research
- Vol. 36 (9) , 2197-2207
Synthesis, molecular docking and ADMET prediction of novel swertiamarin analogues for the restoration of type-2 diabetes: an enzyme inhibition assay
Swertiamarin is a lead, biologically active compound obtained from Enicostemma littorale Blume and known to be identified for the anti-diabetic activity. Present work comprises the synthesis and structural optimization of seven novel swertiamarin analogues and those were not being reported elsewhere till date. Swertiamarin was isolated, followed by modifications that have been accomplished amidst fluorinating, acetylating and oxidizing agents and also performed chromatographic purity and characterization of analogues. Furthermore, the swertiamarin analogues were screened for dipeptidyl peptidase IV (DPP-IV) enzyme inhibition with in silico studies. Besides, the pharmacokinetics and toxicity of analogues were predicted using ADMET software. In a nutshell, the compounds such as SNIPERSV-4 and SNIPERSV-7 have to pose good initial activity (∼48%) in comparison to standard DPP-IV inhibitor (Sitagliptin). The identified analogues were active against DPP-IV enzyme in preliminary screenings, and these findings would be beneficial for the new age researchers also for the therapy of diabetes. Graphical Abstract
- 1 October 2020
- Published by Taylor & Francis in Natural Product Research
- Vol. 36 (9) , 2197-2207
Synthesis, molecular docking and ADMET prediction of novel swertiamarin analogues for the restoration of type-2 diabetes: an enzyme inhibition assay
Swertiamarin is a lead, biologically active compound obtained from Enicostemma littorale Blume and known to be identified for the anti-diabetic activity. Present work comprises the synthesis and structural optimization of seven novel swertiamarin analogues and those were not being reported elsewhere till date. Swertiamarin was isolated, followed by modifications that have been accomplished amidst fluorinating, acetylating and oxidizing agents and also performed chromatographic purity and characterization of analogues. Furthermore, the swertiamarin analogues were screened for dipeptidyl peptidase IV (DPP-IV) enzyme inhibition with in silico studies. Besides, the pharmacokinetics and toxicity of analogues were predicted using ADMET software. In a nutshell, the compounds such as SNIPERSV-4 and SNIPERSV-7 have to pose good initial activity (∼48%) in comparison to standard DPP-IV inhibitor (Sitagliptin). The identified analogues were active against DPP-IV enzyme in preliminary screenings, and these findings would be beneficial for the new age researchers also for the therapy of diabetes. Graphical Abstract
- Open Access
- 7 August 2018
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- Vol. 11 (8) , 40-55
A REVIEW: STATUS OF GENETIC MODULATED NONSMALL CELL LUNG CANCER TARGETS AND TREATMENT (CURRENT UPDATES IN DRUGS FOR NON-SMALL CELL LUNG CANCER TREATMENT)
Genetic modifications or mutations has been a bottleneck for the treatment of cancer; it is widely known to play a vital role in the progression of metastatic level/stage within the nonsmall cell lung cancer (NSCLC). The NSCLC of cancer is responsible for lung cancer lawsuits. In the various genetic mutations related study has been concluded with the various genes findings, which are named as the epidermal growth factor receptor, anaplastic lymphoma kinase, Kristen rat sarcoma virus, ROS proto-oncogene 1, human epidermal growth factor, B-RAF proto-oncogene, rearranged during Transfection, MET, Phosphatidyl 3-kinases CA, IGF-1R, NTRK1, FGFR1, and DDR2. The various research data supported this study. The involvement of the gene in the NSCLC patients made a paradigm shift in the drug discovery. The presence of one mutation in connection with some other could have an impact on NSCLC remedy.Utilizing this genotype-directed therapy for an advanced NSCLC has to turn out to be an appealing and efficacious treatment strategy. Here in the advancement of research, related genetic modulated targets and treatment have been discussed, particular genetic mutations help to find new updated interventions or medicinal drugs for the treatment of NSCLC. In there view, we have comprehensively arranged the mutation type and treatment with the status of NSCLC.
- 7 August 2018
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- Vol. 11 (8) , 40-55
Open AccessA REVIEW: STATUS OF GENETIC MODULATED NONSMALL CELL LUNG CANCER TARGETS AND TREATMENT (CURRENT UPDATES IN DRUGS FOR NON-SMALL CELL LUNG CANCER TREATMENT)
Genetic modifications or mutations has been a bottleneck for the treatment of cancer; it is widely known to play a vital role in the progression of metastatic level/stage within the nonsmall cell lung cancer (NSCLC). The NSCLC of cancer is responsible for lung cancer lawsuits. In the various genetic mutations related study has been concluded with the various genes findings, which are named as the epidermal growth factor receptor, anaplastic lymphoma kinase, Kristen rat sarcoma virus, ROS proto-oncogene 1, human epidermal growth factor, B-RAF proto-oncogene, rearranged during Transfection, MET, Phosphatidyl 3-kinases CA, IGF-1R, NTRK1, FGFR1, and DDR2. The various research data supported this study. The involvement of the gene in the NSCLC patients made a paradigm shift in the drug discovery. The presence of one mutation in connection with some other could have an impact on NSCLC remedy.Utilizing this genotype-directed therapy for an advanced NSCLC has to turn out to be an appealing and efficacious treatment strategy. Here in the advancement of research, related genetic modulated targets and treatment have been discussed, particular genetic mutations help to find new updated interventions or medicinal drugs for the treatment of NSCLC. In there view, we have comprehensively arranged the mutation type and treatment with the status of NSCLC.
- Open Access
- 1 January 2018
- Published by Indo Global Journal of Pharmaceutical Sciences in Indo Global Journal of Pharmaceutical Sciences
- Vol. 8 (3) , 119-123
Phytosome as a Prominent Option in Drug Delivery for the Treatment of the Diseases: A Review
- 1 January 2018
- Published by Indo Global Journal of Pharmaceutical Sciences in Indo Global Journal of Pharmaceutical Sciences
- Vol. 8 (3) , 119-123
Open AccessPhytosome as a Prominent Option in Drug Delivery for the Treatment of the Diseases: A Review